16 April 2024
Napanee, Ontario – NovaVive Inc., an animal health immunobiology company, today announced that an abstract was presented at the 2024 International Embryo Technology Society (IETS) meeting in Denver, CO. The abstract is published in the Reproduction, Fertility and Development journal.
The abstract summarizes a research study evaluating the effect of mycobacterium cell wall fraction (MCWF) (Amplimune®) on reducing the incidence of postpartum bovine metritis in a high-producing Holstein dairy herd. Metritis is a uterine disease that affects up to 40% of dairy cows and commonly develops when pathogenic bacteria infect the uterus after parturition (giving birth).
Adult cows that recently calved were assigned randomly to two groups: MCWF (Amplimune) (n=184) and control (n=156). The MCWF group received an intramuscular dose of 5 ml and the control group received an intramuscular dose of 2 ml of oestradiol cypionate (standard prophylactic protocol at the farm), both at 7 days after parturition.
MCWF treatment reduced (P < 0.05) metritis incidence compared with the control group (11.89% vs 19.87%, respectively). There was a 40% relative reduction of metritis incidence in MCWF-treated cows.
Researchers concluded that a single treatment with MCWF 7 days after parturition shows potential as a preventive treatment to reduce the incidence of metritis in dairy cows. Further research is needed to investigate whether the treatment leads to improved reproduction.
About Amplimune
Amplimune is manufactured in the USA and approved by regulators in the USA, Canada, New Zealand and the United Arab Emirates to reduce the clinical signs and mortality associated with E. coli K99 diarrhea in neonatal calves. The product is an emulsion of mycobacterium cell wall fractions (MCWF) that enhances innate immunity to fight bacterial infections without the use of antibiotics. When injected into the animal, Amplimune enhances both innate and adaptive immune responses to fight bacterial infections. Amplimune is OMRI listed in the U.S. and Canada for use in organic production.
About NovaVive Inc.
NovaVive is a private company founded in July, 2014. The Company has an advanced veterinary immunotherapeutic platform based on mycobacterium cell wall fraction (MCWF) technology with 5 regulator-approved products in the USA (four of these are regulator-approved in Canada; two in Australia; three in New Zealand; and two in the UAE). Certain MCWF formulations have demonstrated the capability of reducing the reliance on antibiotics in the treatment of bacterial diseases of cattle and horses or effectively treating viral equine respiratory disease. Other formulations have been developed as anticancer therapies in dogs and horses. The Company’s development plan is to identify additional livestock and companion animal diseases that may be effectively treated with its immunotherapeutic technology platform. For more information about the Company, please contact:
Graeme McRae, President
Graeme.McRae@NovaVive.ca
Phone: 613-391-3837
or
Jennifer Shea, V-P, Investor Relations & Business Development
Jennifer.Shea@NovaVive.ca
Phone: 613-391-2097